BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 16287142)

  • 21. [Development and establishment of a yeast-based stop codon assay for detection of NF2 gene premature-terminating mutations].
    Kobayashi H
    Hokkaido Igaku Zasshi; 1999 Sep; 74(5):377-86. PubMed ID: 10495852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular biological analysis of neurofibromatosis type 2 gene].
    Ichimura K; Yuasa Y
    Nihon Rinsho; 1993 Sep; 51(9):2462-6. PubMed ID: 8411729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2?
    Murray AJ; Hughes TA; Neal JW; Howard E; Evans DG; Harper PS
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):269-71. PubMed ID: 16421138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
    Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
    J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study.
    Evans DG; Mason S; Huson SM; Ponder M; Harding AE; Strachan T
    J Neurol Neurosurg Psychiatry; 1997 Apr; 62(4):361-6. PubMed ID: 9120449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas.
    Lomas J; Bello MJ; Arjona D; Alonso ME; Martinez-Glez V; Lopez-Marin I; Amiñoso C; de Campos JM; Isla A; Vaquero J; Rey JA
    Genes Chromosomes Cancer; 2005 Mar; 42(3):314-9. PubMed ID: 15609345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.
    Mantripragada KK; Buckley PG; Jarbo C; Menzel U; Dumanski JP
    J Mol Med (Berl); 2003 Jul; 81(7):443-51. PubMed ID: 12830322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of germline NF2 gene rearrangements.
    Legoix P; Sarkissian HD; Cazes L; Giraud S; Sor F; Rouleau GA; Lenoir G; Thomas G; Zucman-Rossi J
    Genomics; 2000 Apr; 65(1):62-6. PubMed ID: 10777666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neurofibromatosis].
    Wolkenstein P; Decq P
    Neurochirurgie; 1998 Nov; 44(4):267-72. PubMed ID: 9864698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
    Kley N; Seizinger BR
    Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ring chromosome 22 and neurofibromatosis type II: proof of two-hit model for the loss of the NF2 gene in the development of meningioma.
    Zirn B; Arning L; Bartels I; Shoukier M; Hoffjan S; Neubauer B; Hahn A
    Clin Genet; 2012 Jan; 81(1):82-7. PubMed ID: 21175598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma].
    Sanson M
    Rev Neurol (Paris); 1996 Jan; 152(1):1-10. PubMed ID: 8729390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
    Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG
    Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction.
    Diebold R; Bartelt-Kirbach B; Evans DG; Kaufmann D; Hanemann CO
    J Mol Diagn; 2005 Feb; 7(1):97-104. PubMed ID: 15681480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma.
    Paganini I; Capone GL; Vitte J; Sestini R; Putignano AL; Giovannini M; Papi L
    J Neurooncol; 2018 Mar; 137(1):33-38. PubMed ID: 29230670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The mouse neurofibromatosis type 2 gene maps to chromosome 11.
    Claudio JO; Malo D; Rouleau GA
    Genomics; 1994 May; 21(2):437-9. PubMed ID: 8088840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schwannomatosis: a genetic and epidemiological study.
    Evans DG; Bowers NL; Tobi S; Hartley C; Wallace AJ; King AT; Lloyd SKW; Rutherford SA; Hammerbeck-Ward C; Pathmanaban ON; Freeman SR; Ealing J; Kellett M; Laitt R; Thomas O; Halliday D; Ferner R; Taylor A; Duff C; Harkness EF; Smith MJ
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1215-1219. PubMed ID: 29909380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.